Search Result

Results for "

CDK4/6

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Androgen Receptor (1) Apoptosis (5) Bcl-2 Family (1) c-Met/HGFR (1) c-Myc (2) Caspase (1) CDK (62) DNA Alkylator/Crosslinker (1) E3 Ligase Ligand-Linker Conjugates (1) EGFR (1) Epigenetic Reader Domain (1) Estrogen Receptor/ERR (1) HDAC (1) Ligands for Target Protein for PROTAC (3) MDM-2/p53 (1) Molecular Glues (2) p38 MAPK (1) PARP (1) PI3K (1) PROTACs (7) Raf (1) Ser/Thr Protease (1)
By Research Areas:	Cancer (66)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-112418

CDK4/6-IN-18	CDK	Cancer
CDK4/6-IN-18 (Example 2BrIC) is a selective *CDK4/6* inhibitor. CDK4/6-IN-18 inhibits ionizing radiation (IR)-induced DNA damage in cells .

HY-164376

CDK4/6-IN-21	CDK	Cancer
CDK4/6-IN-21 (compound I-52) is a *CDK4/6* inhibitor with IC₅₀ values of 3.88 and 3.31 nM for CDK4 and CDK6, respectively. CDK4/6-IN-21 has antitumor activity .

HY-164376A

CDK4/6-IN-21 maleate	CDK	Cancer
CDK4/6-IN-21 maleate (compound I-52) is a *CDK4/6* inhibitor with IC₅₀ values of 3.88 and 3.31 nM for CDK4 and CDK6, respectively. CDK4/6-IN-21 maleate has antitumor activity .

HY-146213

CDK4/6-IN-12	CDK	Cancer
CDK4/6-IN-12 is a potent cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. CDK4/6-IN-12 has enzymatic inhibitory activity for CDK4 and CDK6 with IC₅₀ of 592.3 nM and 3090 nM, respectively. CDK4/6-IN-12 can be used for the research of cancer .

HY-112280

Crozbaciclib CDK4/6/1 Inhibitor	CDK	Cancer
Crozbaciclib (CDK4/6/1 Inhibitor) is a *CDK4/6* inhibitor with IC₅₀s of 3 and 1 nM, respectively.

HY-146214

CDK4/6-IN-13	CDK	Cancer
As a cdk4/6 inhibitor. Compounds 10B and 10C showed low nanomolar activity, ideal antiproliferative activity, excellent metabolic properties and acceptable pharmacokinetics on cdk4/6.

HY-143257

CDK4/6-IN-7	CDK	Cancer
CDK4/6-IN-7 is a potent, selective and orally active *CDK4/6* inhibitor, with IC₅₀s of 1.58 and 4.09 nM, respectively. CDK4/6-IN-7 can be used for the research of breast cancer .

HY-115992

CDK4/6-IN-9	CDK	Cancer
CDK4/6-IN-9 (compound 10) is a selective *CDK4/6* inhibitor with an IC₅₀ of 905 nM for CDK6/cyclin D1. CDK4/6-IN-9 has the potential for multiple myeloma (MM) research .

HY-153704

CDK4/6-IN-17	CDK	Cancer
CDK4/6-IN-17 (compound 12) is an orally active *CDK4/6* inhibitor with IC₅₀ ranging of 10-100 nM in BE(2) cells. CDK4/6-IN-17 inhibits tumor growth in COLO205 xenograft model .

HY-142076

CDK4/6-IN-15	CDK	Cancer
CDK4/6-IN-15 is an orally active and selective *CDK4/6* inhibitor. CDK4/6-IN-15 potently inhibits cancer cells growth. CDK4/6-IN-15 arrests cell cycle at G1 phase and suppresses retinoblastoma tumour suppressor protein (Rb) phosphorylation at S780 and E2 factor (E2F)-regulated gene expression .

HY-142076A

CDK4/6-IN-15 hydrochloride	CDK	Cancer
CDK4/6-IN-15 hydrochloride is an orally active and selective *CDK4/6* inhibitor. CDK4/6-IN-15 hydrochloride potently inhibits cancer cells growth. CDK4/6-IN-15 hydrochloride arrests cell cycle at G1 phase and suppresses retinoblastoma tumour suppressor protein (Rb) phosphorylation at S780 and E2 factor (E2F)-regulated gene expression .

HY-153088

CDK4/6-IN-16	CDK	Cancer
CDK4/6-IN-16 (example 195) is a potent *CDK4* and *CDK6* inhibitor, with an IC₅₀ of 0.013 μM for *CDK4. CDK4/6-IN-16 can be used for the research of CDK4*-mediated disorders, such as cancer .

HY-126244

CDK4/6-IN-3	CDK	Cancer
CDK4/6-IN-3 is a brain-penetrant *CDK4/CDK6* inhibitor with K_is of <0.3 nM and 2.2 nM, respectively. CDK4/6-IN-3 inhibits CDK1 with a K_i of 110 nM. CDK4/6-IN-3 can be used for the treatment of glioblastoma .

HY-115993

CDK4/6-IN-10	CDK Apoptosis	Cancer
CDK4/6-IN-10 is a potent, selective and orally active *CDK4* and *CDK6* inhibitor with IC₅₀s of 22 nM and 10 nM, respectively. CDK4/6-IN-10 shows antitumor activity. CDK4/6-IN-10 has the potential for the research of Multiple myeloma (MM) .

HY-161978

CDK4/6-IN-22	CDK	Cancer
CDK4/6-IN-22 (Compound 1-A) is a *CDK4* and *CDK6* dual inhibitor .

HY-162529

CDK4/6-IN-19	CDK	Cancer
CDK4/6-IN-19 (Compound II-7) is a *CDK4/CDK6* inhibitor with IC₅₀ values of 0.2, 5.0 nM, respectively. CDK4/6-IN-19 also inhibits cell proliferation and can be used in cancer research .

HY-162530

CDK4/6-IN-20	CDK	Cancer
CDK4/6-IN-20 (Compound II-5) is a *CDK4/CDK6* inhibitor with IC₅₀ values of 1.9, 14.2 nM, respectively. CDK4/6-IN-20 also inhibits cell proliferation and can be used in cancer research .

HY-144995

BSJ-02-162 CDK4/6-IN-11	PROTACs CDK	Cancer
CDK4/6-IN-11 is a potent PROTAC CDK4/6 degrader . CDK4/6-IN-11 consists of a thalidomide-based E3 ligase ligand (blue part) Thalidomide-NH-CH2-COOH (HY-131717), a target protein ligand (red part) Palbociclib (HY-50767), and a PROTAC linker (black part) Boc-NH-C4-Br (HY-W007803). E3 ligase ligand and linker can form Thalidomide-NH-amido-C4-Br (HY-170307).

HY-143258

CDK4/6-IN-8	CDK	Cancer
CDK4/6-IN-8 (Compound 7p) is a selective *CDK4* and *CDK6* inhibitor with IC₅₀ values of 5.01 nM and 3.97 nM, respectively .

HY-151898

CDK4/6-IN-14	CDK	Cancer
CDK4/6-IN-14 is a potent and highly selective *CDK4* and *CDK6* (CDK) inhibitor with IC₅₀s of 10 nM and 16 nM, respectively. CDK4/6-IN-14 exhibits more than 60-fold selectivity over CDKs 1, 2, 7, and 9, and shows high selectivity among other 205 kinases .

HY-114339

CDK4/6-IN-2	CDK	Cancer
CDK4/6-IN-2 is a potent *CDK4* and *CDK6* inhibitor extracted from patent US20180000819A1, Compound 1, has IC₅₀s of 2.7 and 16 nM for CDK4 and CDK6, respectively .

HY-139449

CDK4/6-IN-5	CDK	Cancer
CDK4/6-IN-5 is a potent *CDK4* and *CDK6* inhibitor with K_is of 0.2 and 4.4 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3, respectively . (from patent WO2019207463A1 example A93).

HY-139450

Atirmociclib PF-07220060; CDK4/6-IN-6	CDK	Cancer
Atirmociclib (PF-07220060; example A94) is a potent *CDK4/CDK6* inhibitor with a K_i of 0.6 nM and 13.9 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3, respectively .

HY-152263

*HEMTAC CDK4/6* degrader 1**	PROTACs CDK Apoptosis	Cancer
HEMTAC CDK4/6 degrader 1 is a PROTAC connected by ligands for HSP90 and *CDK4/6* with a K_d value of 35.7 μM. HEMTAC CDK4/6 degrader 1 induces CDK4/6 degradation in B16F10 melanoma cells. HEMTAC CDK4/6 degrader 1 arrests cell cycle at G0/G1 phase and induces apoptosis. HEMTAC CDK4/6 degrader 1 can be used in research of cancer . HEMTAC CDK4/6 degrader 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-163786

*PROTAC CDK4/6* degrader 1**	PROTACs CDK Apoptosis	Cancer
PROTAC CDK4/6 degrader 1 (Compound 7f) is a dual degrader for *CDK4* and *CDK6* with DC₅₀ of 10.5 and 2.5 nM. PROTAC CDK4/6 degrader 1 inhibits the proliferation of cell Jurkat (IC₅₀ is 0.18 μM), arrests the cell cycle at G1 phase and induces apoptosis. (Pink: ligand for target protein YY173 (HY-163787); Black: linker (HY-163788); Blue: ligand for E3 ligase (HY-10984))

HY-138946

XY028-140	CDK PROTACs	Cancer
XY028-140 is a PROTAC connected by ligands for Cereblon and *CDK. XY028-140 inhibits both CDK4/6 expression and CDK4*/6 activity in cancer cells .

HY-16297A

Abemaciclib Maximum Cited Publications 82 Publications Verification LY2835219	CDK	Cancer
Abemaciclib (LY2835219) is a selective *CDK4/6* inhibitor with IC₅₀ values of 2 nM and 10 nM for CDK4 and CDK6, respectively.

HY-112280A

Crozbaciclib fumarate	CDK	Cancer
Crozbaciclib fumarate is a *CDK4/6* inhibitor with IC₅₀s of 3 and 1 nM, respectively.

HY-16297

Abemaciclib methanesulfonate Maximum Cited Publications 82 Publications Verification LY2835219 methanesulfonate	CDK	Cancer
Abemaciclib methanesulfonate (LY2835219 methanesulfonate) is a selective *CDK4/6* inhibitor with IC₅₀s of 2 nM and 10 nM for CDK4 and CDK6, respectively .

HY-16297AS

Abemaciclib-d8 LY2835219-d₈	CDK	Cancer
Abemaciclib-d₈ is the deuterium labeled Abemaciclib. Abemaciclib (LY2835219) is a selective CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively.

HY-16297AR

Abemaciclib (Standard)	CDK	Cancer
Abemaciclib (Standard) is the analytical standard of Abemaciclib. This product is intended for research and analytical applications. Abemaciclib (LY2835219) is a selective *CDK4/6* inhibitor with IC₅₀ values of 2 nM and 10 nM for CDK4 and CDK6, respectively.

HY-112272

Lerociclib 1 Publications Verification G1T38	CDK	Cancer
Lerociclib (G1T38) is a potent and selective inhibitor of *CDK4/6, with IC₅₀s* of 1 nM, 2 nM for CDK4/CyclinD1 and CDK6/CyclinD3, respectively.

HY-101467AR

Trilaciclib hydrochloride (Standard)	CDK	Cancer
Trilaciclib (hydrochloride) (Standard) is the analytical standard of Trilaciclib (hydrochloride). This product is intended for research and analytical applications. Trilaciclib hydrochloride (G1T28 hydrochloride) is a *CDK4/6* inhibitor with IC₅₀s of 1 nM and 4 nM for CDK4 and CDK6, respectively .

HY-129336

Abemaciclib metabolite M20 4 Publications Verification LSN3106726	CDK	Cancer
Abemaciclib metabolite M20 (LSN3106726), the active metabolite of Abemaciclib, is a selective *CDK4*/6 inhibitor for the treatment of cancer .

HY-153336

CDK-IN-12	CDK	Cancer
CDK-IN-12 (Example 20) is a CDK Inhibitor. CDK-IN-12 Inhibits CDK4/6 with IC₅₀ values less than 20 nM .

HY-16297R

Abemaciclib methanesulfonate (Standard)	CDK	Cancer
Abemaciclib (methanesulfonate) (Standard) is the analytical standard of Abemaciclib (methanesulfonate). This product is intended for research and analytical applications. Abemaciclib methanesulfonate (LY2835219 methanesulfonate) is a selective CDK4/6 inhibitor with IC50s of 2 nM and 10 nM for CDK4 and CDK6, respectively .

HY-163787

YY173	CDK	Cancer
YY173 is a dual inhibitor for *CDK4* and *CDK6* with IC₅₀ of 7.7 and 88 nM. YY173 inhibits the proliferation of cell Jurkat with an IC₅₀ of 1.46 μM. YY173 can be used for synthesis of PROTAC CDK4/6 degrader 1 (HY-163786) .

HY-129180

XY028-133	PROTACs CDK	Cancer
XY028-133 (example 14) is a PROTAC-based *CDK4/6* degrader with anti-tumor activity, which consists of ligands for von Hippel-Lindau and *CDK* .

HY-137449

Rintodestrant G1T48	Estrogen Receptor/ERR CDK	Cancer
Rintodestrant (G1T48) is an orally active, non-steroidal and selective estrogen receptor degrader. Rintodestrant (G1T48) is also a *CDK4/6* inhibitor .

HY-101467A

Trilaciclib hydrochloride 1 Publications Verification G1T28 hydrochloride	CDK	Cancer
Trilaciclib (G1T28) hydrochloride is an orally active *CDK4/6* inhibitor with IC₅₀ values of 1 nM and 4 nM for CDK4 and CDK6, respectively. Trilaciclib hydrochloride can effectively inhibit tumor cell proliferation and reduce the hematological toxicity caused by chemotherapy. Trilaciclib hydrochloride attenuates apoptosis and myelosuppression induced by 5FU (HY-90006) chemotherapy .

HY-101467

Trilaciclib 1 Publications Verification G1T28	CDK	Cancer
Trilaciclib (G1T28) is an orally active *CDK4/6* inhibitor with IC₅₀ values of 1 nM and 4 nM for CDK4 and CDK6, respectively. . Trilaciclib can effectively inhibit tumor cell proliferation and reduce the hematological toxicity caused by chemotherapy. Trilaciclib attenuates apoptosis and myelosuppression induced by 5FU (HY-90006) chemotherapy .

HY-15777A

Ribociclib hydrochloride 50+ Cited Publications LEE011 hydrochloride	CDK	Cancer
Ribociclib hydrochloride (LEE011 hydrochloride) is a highly specific *CDK4/6* inhibitor with IC₅₀ values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex.

HY-15777B

Ribociclib succinate 50+ Cited Publications LEE011 succinate	CDK	Cancer
Ribociclib succinate (LEE011 succinate) is a highly specific *CDK4/6* inhibitor with IC₅₀ values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex.

HY-15777C

Ribociclib succinate hydrate 50+ Cited Publications LEE011 succinate hydrate	CDK	Cancer
Ribociclib succinate hydrate (LEE011 succinate hydrate) is a highly specific *CDK4/6* inhibitor with IC₅₀ values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex.

HY-129336S

Abemaciclib metabolite M20-d8 LSN3106726-d₈	CDK	Cancer
Abemaciclib metabolite M20-d₈ is the deuterium labeled Abemaciclib metabolite M20. Abemaciclib metabolite M20 (LSN3106726), the active metabolite of Abemaciclib, is a selective CDK4/6 inhibitor[1].

HY-15777

Ribociclib 50+ Cited Publications LEE011	CDK	Cancer
RRibociclib (LEE011) is an ATP-competitive and orally active CDK4/6 inhibitor with IC₅₀ values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex .

HY-126534

Abemaciclib metabolite M18 LSN3106729	Ligands for Target Protein for PROTAC CDK	Cancer
Abemaciclib metabolite M18 (LSN3106729), the metabolite of Abemaciclib (HY-16297A), is a *CDK* inhibitor with antitumor activity. Abemaciclib metabolite M18 and a CRBN ligand have been used to design PROTAC CDK4/6 degrader .

HY-126534A

Abemaciclib metabolite M18 hydrochloride 1 Publications Verification LSN3106729 hydrochloride	Ligands for Target Protein for PROTAC CDK	Cancer
Abemaciclib metabolite M18 (LSN3106729) hydrochloride, the metabolite of Abemaciclib (HY-16297A), is a *CDK* inhibitor with antitumor activity. Abemaciclib metabolite M18 hydrochloride and a CRBN ligand have been used to design PROTAC CDK4/6 degrader .

HY-136250

BSJ-03-204	PROTACs CDK	Cancer
BSJ-03-204 is a PROTAC connected by ligands for Cereblon and *CDK. BSJ-03-204 is a potent and selective Palbociclib-based CDK4/6* dual degrader (PROTAC), with IC₅₀s of 26.9 nM and 10.4 nM for CDK4/D1 and CDK6/D1, respectively. BSJ-03-204 does not induce IKZF1/3 degradation and has anti-cancer activity .

HY-131890

VH032 amide-PEG1-acid	DNA Alkylator/Crosslinker E3 Ligase Ligand-Linker Conjugates	Cancer
VH032 amide-PEG1-acid (linker 10) is a VHL-1 alkyl linker that can be used to bind *CDK4/6* ligands (PI) and degradation/destruction tags (EL) (e.g.,E3 ligase ligands) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-127057

Lambertianic acid	Pinus lambertiana Douglas Structural Classification Pinaceae Terpenoids Source classification Diterpenoids Plants	Androgen Receptor CDK MDM-2/p53 Apoptosis Caspase PARP Bcl-2 Family
Lambertianic acid is a bioactive diterpene with anti-allergic, antibacterial and anticancer activities. Lambertianic acid decreases androgen receptor protein levels, cellular and secretory levels of prostate-specific antigen. Lambertianic acid also suppresses cell proliferation by inducing G1 arrest, downregulating CDK4/6 and cyclin D1, activating p53, p21 and p27. Lambertianic acid induces Apoptosis and the expression of related proteins, including cleaved caspase-3/9, c-PARP and BAX, and inhibited BCl-2. Lambertianic acid is promising for research of prostate cancer .

Cat. No.	Product Name	Chemical Structure

HY-16297AS

Abemaciclib-d8
Abemaciclib-d₈ is the deuterium labeled Abemaciclib. Abemaciclib (LY2835219) is a selective CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively.

HY-129336S

Abemaciclib metabolite M20-d8
Abemaciclib metabolite M20-d₈ is the deuterium labeled Abemaciclib metabolite M20. Abemaciclib metabolite M20 (LSN3106726), the active metabolite of Abemaciclib, is a selective CDK4/6 inhibitor[1].

HY-15777AS

Ribociclib-d6 hydrochloride
Ribociclib-d₆ (hydrochloride) is a deuterium labeled Ribociclib. Ribociclib is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex[1].

HY-15777S1

Ribociclib-d8
Ribociclib-d₈ is the deuterium labeled Ribociclib[1]. Ribociclib (LEE01) is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex[2].

HY-126534S

Abemaciclib metabolite M18-d8
Abemaciclib metabolite M18-d₈ is the deuterium labeled Abemaciclib metabolite M18. Abemaciclib metabolite M18 (LSN3106729), the metabolite of Abemaciclib (HY-16297A), is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 and a CRBN ligand have been used to design PROTAC CDK4/6 degrader[1][2].

HY-15777S

Ribociclib-d6
Ribociclib-d₆ is a deuterium labeled Ribociclib. Ribociclib is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex[1].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

CDK4/6

Inhibitors & Agonists

NaturalProducts

Isotope-Labeled Compounds

Natural
Products